Translating cancer ‘omics’ to improved outcomes
- Emily A. Vucic1,2,6,7,
- Kelsie L. Thu1,6,
- Keith Robison3,
- Leszek A. Rybaczyk4,
- Raj Chari1,2,5,
- Carlos E. Alvarez4 and
- Wan L. Lam1,2
- 1British Columbia Cancer Research Centre, Vancouver V5Z 1L3, Canada;
- 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver V6T 1Z4, Canada;
- 3Warp Drive Bio, Cambridge, Massachusetts 02142, USA;
- 4Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio 43205, USA;
- 5Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
-
↵6 These authors contributed equally to this work.
Abstract
The genomics era has yielded great advances in the understanding of cancer biology. At the same time, the immense complexity of the cancer genome has been revealed, as well as a striking heterogeneity at the whole-genome (or omics) level that exists between even histologically similar tumors. The vast accrual and public availability of multi-omics databases with associated clinical annotation including tumor histology, patient response, and outcome are a rich resource that has the potential to lead to rapid translation of high-throughput omics to improved overall survival. We focus on the unique advantages of a multidimensional approach to genomic analysis in this new high-throughput omics age and discuss the implications of the changing cancer demographic to translational omics research.
Footnotes
-
↵7 Corresponding author.
E-mail evucic{at}bccrc.ca.
-
Article and publication date are at http://www.genome.org/cgi/doi/10.1101/gr.124354.111.
- Copyright © 2012 by Cold Spring Harbor Laboratory Press
